| Id: | acc4790 |
| Group: | 1sens |
| Protein: | Akt |
| Gene Symbol: | Akt1 |
| Protein Id: | P31750 |
| Protein Name: | AKT1_MOUSE |
| PTM: | phosphorylation |
| Site: | Thr308 |
| Site Sequence: | GIKDGATMKTFCGTPEYLAPE |
| Disease Category: | Endocrine and metabolic diseases |
| Disease: | Plasmalogen Deficiency |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | TDG |
| Drug Info: | "TDG is a drug, but specific information about its nature, use and mechanism is not provided here." |
| Effect: | modulate |
| Effect Info: | Plasma phospholipid deficiency inhibits the activation of AKT. We found that inhibiting the phosphorylation of AKT at Ser473 and Thr308 was sufficient to induce the distal relocation of the AIS. Short-chain alkyl glycerols (such as TDG) can restore the synthesis of plasmalogens and reverse the distal displacement of the AIS. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 34302896 |
| Sentence Index: | 34302896_7 |
| Sentence: | "Plasmalogen deficiency impaired AKT activation, and we show that inhibition of AKT phosphorylation at Ser473 and Thr308 is sufficient to induce a distal relocation of the AIS." |
Sequence & Structure:
MNDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQRESPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWATAIQTVADGLKRQEEETMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPTQRLGGGSEDAKEIMQHRFFANIVWQDVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 308 | U | Prostate cancer | Phosphorylation | 37384528 |
| T | 308 | U | Hepatocellular carcinoma | Phosphorylation | 33500384 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
